Avita Medical's ReCell® Recognized as Innovative Treatment for Burn Victims

Unique Regenerative Technology Featured in Army Technology Magazine July/August Issue

---

Northridge, CA and Cambridge, United Kingdom, 20 July 2015 — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today said a branch of the U.S. Military says the U.S. Department of Defense 'wants to use' the company's ReCell® technology, which it described as offering a possible 'paradigm shift' in skin injury treatment.

The July/August 2015 issue of *Army Technology Magazine*, in an article titled "Innovative treatments offer hope for burn victims," explored new strategies being evaluated by the Armed Forces Institute of Regenerative Medicine. The Fort Detrick, Maryland-based group has a stated goal to resolve if regenerative medicine – with its potential to use a patient's own repair mechanisms – can be used to heal traumatic wounds faster, and reduce scarring, contractures and disability amongst U.S. military personnel.

"The DOD wants to use these technologies to treat complex traumatic injuries," explained Kristi Pottol, Program Director of the Tissue Injury and Regenerative Medicine Project Management Office.

The article explained how Avita Medical's device took only 30 minutes to use a patient's own cells to create a healing suspension, which can treat a skin wound 80 times larger than the skin sample taken. The device was one of two regenerative medicine technologies covered in the article, which explained that "ReCell speeds the healing process, decreases the need to harvest skin from donor sites and improves the appearance of the burn scars."

Dr. Wendy Dean, a medical advisor at the Tissue Injury and Regenerative Medicine Program Management Office said that technologies such as ReCell "could be the first substantial change in how burn and skin injuries are treated in the last half century…. sparing burn patients the pain of large donor sites, or offering surgeons a ready-made, permanent option for wound coverage could lead to a paradigm shift in skin injury treatment."

The device has already been used on US personnel wounded in Afghanistan under special compassionate use dispensations. Some of the work has been performed at the Walter Reed National Military Medical Center in Bethesda, Maryland, the nation's leading military hospital.

"For a medical device to be useful for combat injuries, it must be easy to use and deploy, and we believe ReCell meets these criteria, being portable and completely self-contained," commented Adam Kelliher, Chief Executive Officer of Avita Medical. "Using it quickly will make it more effective on burns and other skin wounds, and this is why we think it is an ideal tool for military physicians."

ABOUT RECELL® AND RES™

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION

Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
akelliher@avitamedical.com

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
trooney@avitamedical.com

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone: +61(0) 8 9474 7738
gabriel@laurus.net.au

The Ruth Group
Lee Roth, Investor Relations
Kirsten Thomas, Public Relations
Phone: +1 (646) 536-7012 / 7014
lroth@theruthgroup.com
/ kthomas@theruthgroup.com